Oncoloxía médica
Servizo
Carlos
Camps Herrero
Publicacións nas que colabora con Carlos Camps Herrero (31)
2024
-
Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients
Archivos de Bronconeumologia, Vol. 60, Núm. 2, pp. 88-94
-
Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry
Lung Cancer, Vol. 190
-
Difficulties on the access to innovative targeted therapies for lung cancer in Spain
Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 597-612
2023
-
Addressing lung cancer screening eligibility in Spain using 2013 and 2021 US Preventive Service Task Force criteria: cross-sectional study
ERJ Open Research, Vol. 9, Núm. 6
-
Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer
Thrombosis Research, Vol. 232, pp. 133-137
2022
-
Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics
BMC Cancer, Vol. 22, Núm. 1
-
Increased quality of life in patients with breakthrough cancer pain after individualized therapy: the CAVIDIOM study
Future oncology (London, England), Vol. 18, Núm. 35, pp. 3913-3927
-
Measures to evaluate quality of care in renal cancer: results of a Delphi study in Spain
Clinical and Translational Oncology, Vol. 24, Núm. 3, pp. 495-502
2021
-
Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications
JCO oncology practice, Vol. 17, Núm. 8, pp. e1162-e1169
-
NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment
Molecular Oncology, Vol. 15, Núm. 9, pp. 2363-2376
-
Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data
BMC Cancer, Vol. 21, Núm. 1
2020
-
Development of a multicriteria decision analysis framework for evaluating and positioning oncologic treatments in clinical practice
Journal of Oncology Practice
-
Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation
Cancer Epidemiology, Vol. 67
2019
-
Active study: undetected prevalence and clinical inertia in the treatment of breakthrough cancer pain (BTcP)
Clinical and Translational Oncology, Vol. 21, Núm. 3, pp. 380-390
-
Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non–Small Cell Lung Cancer
Journal of Thoracic Oncology, Vol. 14, Núm. 2, pp. 304-310
-
Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance
Lung Cancer, Vol. 134, pp. 72-78
-
Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping
Annals of Oncology, Vol. 30, Núm. 2, pp. 290-296
-
Identification of a novel synthetic lethal vulnerability in non-small cell lung cancer by co-targeting TMPRSS4 and DDR1
Scientific Reports, Vol. 9, Núm. 1
-
Lung cancer in Spain: Information from the Thoracic Tumors Registry (TTR study)
Translational Lung Cancer Research, Vol. 8, Núm. 4, pp. 461-475
2018
-
Assessment and treatment of breakthrough cancer pain in Spain: A self-audit study
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii611-viii612